Gary Sandhu, MD
Hospitalist · Pomona, CANPI 1871513002
Payments from drug & device makers
What this record shows
20 manufacturers reported payments, led by Davol Inc. at 58.8% of the total. Reporting peaked in 2020 at $2,101 and has fallen 85.0% since, to $315 in 2025. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $38.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$2K
- E.r. Squibb & Sons, L.L.C.$335
- Kestra Medical Technology Services, Inc.$310
- Johnson & Johnson$278
- Procept Biorobotics Corporation$125
- Novartis$98
- plus $524 from 14 others
What the payments were for
- Travel & lodging$2,38559%
- Food & beverage$1,66941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 7 | $2,385 |
| E.r. Squibb & Sons, L.L.C. | 20 | $335 |
| Kestra Medical Technology Services, Inc. | 32 | $310 |
| Johnson & Johnson | 18 | $278 |
| Procept Biorobotics Corporation | 1 | $125 |
| Novartis | 5 | $98 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $74 |
| Abiomed | 1 | $54 |
| Boehringer Ingelheim | 2 | $50 |
| Sumitomo Pharma America, Inc. | 1 | $44 |
| AstraZeneca | 3 | $44 |
| Boston Scientific | 1 | $43 |
| Pfizer | 2 | $43 |
| Merck | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Novo Nordisk | 2 | $35 |
| Travere Therapeutics, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $12 |
| CMP Pharma, Inc. | 1 | $12 |
| Cook Medical LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROGEL$2,385
- AQUABEAM SYSTEM$125
How this compares
$4,054 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 424 | $116,596 |
| AvycazCeftazidime/Avibactam | 16 | $54,359 |
| SantylCollagenase Clostridium Hist. | 41 | $44,088 |
| Pantoprazole Sodium | 197 | $30,051 |
| XareltoRivaroxaban | 85 | $23,908 |
| JardianceEmpagliflozin | 80 | $22,897 |
| EntrestoSacubitril/Valsartan | 80 | $22,732 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $18,496 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 106 | $16,638 |
| Sevelamer Hcl | 26 | $15,135 |
| ErtapenemErtapenem Sodium | 42 | $14,289 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $11,751 |
| FarxigaDapagliflozin Propanediol | 37 | $11,178 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,244 |
| Potassium Chloride | 123 | $9,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $43 | $123,503446 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma, Brilinta | $44 | $31,00699 claims |
| Johnson & JohnsonXarelto | $278 | $23,90885 claims |
| Boehringer IngelheimJardiance | $50 | $22,89780 claims |
| NovartisEntresto | $98 | $22,73280 claims |
| MerckJanuvia, Janumet | $40 | $12,93844 claims |
| Lilly USA, LLCHumalog | $12 | $3,49350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.
Other hospitalist in Pomona
- Jennifer SchneiderSanta Rosa$1.2M
- Soham ShahBakersfield$844K
- Alpesh AminOrange$428K
- Retha GoodglickSanta Monica$156K
- Robert WachterSan Francisco$75K
- Steven WongTorrance$36K
- Edward LeeLos Angeles$30K
- Anjani KolahiOrange$30K
- Omar AldaasSan Diego$24K
- Summaiya MuhammadCastro Valley$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.